BCL2 and breast cancer: To determine whether primary breast cancer could be targeted by a therapeutic strategy that reactivates MYC’s apoptotic potential via BH3 mimetics, we assessed the expression of MYC, BCL-2, BCL-XL, and MCL-1 using a tissue microarray (TMA) of 231 primary breast cancer samples.